Medications Requiring Lifelong Continuation
Once started, antihypertensive medications should be maintained lifelong, even beyond age 85 years, if well tolerated 1. This represents the clearest evidence-based recommendation for indefinite medication continuation.
Antihypertensive Therapy
The 2024 ESC guidelines explicitly state that BP-lowering drug treatment should be maintained lifelong, even beyond the age of 85 years, if well tolerated 1. This recommendation applies to:
- ACE inhibitors or ARBs
- Calcium channel blockers (CCBs)
- Thiazide/thiazide-like diuretics
- Beta-blockers (when indicated for compelling reasons: post-MI, heart failure with reduced ejection fraction, angina, or heart rate control)
The rationale is straightforward: hypertension is a chronic condition requiring continuous management to prevent cardiovascular morbidity and mortality. The 2025 AHA/ACC guidelines reinforce this by emphasizing that resistant hypertension patients require ongoing combination therapy, typically starting with an ACE inhibitor or ARB plus CCB and thiazide-like diuretic 2.
Important Caveats for Antihypertensives
- Tolerability is key: If medications are poorly tolerated, the target should follow the "as low as reasonably achievable" (ALARA) principle rather than complete discontinuation 1
- Real-world persistence is poor: Only 39% of patients continue antihypertensive therapy continuously for 10 years in practice 3, and 52.7% remain persistent over 5 years 4, despite the lifelong indication
- Treatment modifications are common early: 53.5% of persistent patients undergo treatment changes in the first year, but stability increases thereafter 4
Secondary Prevention After Coronary Heart Disease
For patients with established coronary heart disease (CHD), the following combination should be continued indefinitely:
- Aspirin
- Statins
- At least 2 blood pressure-lowering drugs
Research shows that 81% of CHD patients are prescribed this combination at discharge, with three-quarters remaining on it after 2 years, maintaining an expected preventive effect of 74% 5. The evidence demonstrates that these medications need to be continued indefinitely to maximize cardiovascular event prevention.
Antidepressants
Continuation therapy of 3-6 months after acute stabilization should be considered standard for all depressed patients, and maintenance therapy should be considered for many depressed patients 6. Depression is a recurrent, often chronic, lifetime illness. For patients at high risk for recurrence:
- Continue active treatment at the original dose indefinitely
- Recurrence rates are significantly lower with continued treatment versus placebo
- SSRIs are preferable to tricyclics for long-term treatment due to superior tolerability and safety
The decision for truly "lifelong" continuation depends on individual recurrence risk, but many patients with recurrent depression require indefinite treatment.
Medications That Are NOT Lifelong
Antiseizure Medications
These can potentially be discontinued after a period of seizure freedom per guidelines, though the decision is highly individualized based on seizure risk, medication side effects, and patient preferences 7.
Preventive Medications at End of Life
Medications deemed inappropriate in palliative care contexts (per STOPPFrail criteria) may be discontinued, though symptomatic medications may be reinitiated for comfort 8.
Clinical Pitfalls to Avoid
Don't assume patients will continue medications: Real-world persistence is dramatically lower than clinical trial adherence. Active monitoring and patient education are essential.
Don't discontinue antihypertensives in elderly patients: The evidence explicitly supports continuation beyond age 85 if tolerated 1.
Don't stop secondary prevention after CHD: The combination of antiplatelet, statin, and BP-lowering therapy should continue indefinitely 5.
Don't overlook medication interference: In resistant hypertension, carefully review all medications (including over-the-counter NSAIDs and decongestants) that may interfere with BP control 2.